Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.
Read more(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.
Read more(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.
Read more(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.
Read more
(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.
Read more(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.
Read more(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:
Read more(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.
Read more(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.
Read more(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.
Read more(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.
Read more(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.
Read more(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.
Read more(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.
Read more
Last checked at